ArticleJournal of multidisciplinary healthcare2025
Potential Causal Relationship Between Plasma and Cerebrospinal Fluid Metabolites and Meningioma: Two-Sample Mendelian Randomization Study.
Article in Journal of multidisciplinary healthcare, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Meningioma (MGM) is the most common benign intracranial tumor and ranks as the second most frequent intracranial tumor in terms of incidence, following malignant gliomas. Studying the metabolites in the serum and cerebrospinal fluid (CSF) of patients with MGM is crucial for understanding the underlying biological mechanisms, identifying new biomarkers, and developing novel therapeutic strategies. Methods: Mendelian randomization (MR) is a powerful analytical approach that leverages genetic variants to assess potential causal relationships between exposures and outcomes. In this study, MR analysis was used to investigate the causal relationships between 486 serum metabolites, 338 CSF metabolites, and MGM. Our MGM data was derived from the genome wide association studies (GWASs) dataset in the FinnGen database, comprising 1,835 cases of European ancestry and 377,674 controls. The data for 486 plasma metabolites was obtained from the GWAS catalog, and the data for 338 CSF metabolites was obtained from the Wisconsin Alzheimer's Disease Research Center (WADRC) and Wisconsin Alzheimer's Disease Prevention Registry (WRAP) study collections. We mainly utilized the Inverse Variance Weighted (IVW) approach to evaluate the causal association between metabolites and MGMs, supplemented by four additional methods to further validate and strengthen our findings. False discovery rate (FDR) correction was applied (q<0.05) to control the false-positive rate. Results: Through MR analysis, the study identified 19 plasma metabolites and 17 CSF metabolites demonstrating potential causal associations with MGMs. Among these, 14 metabolites indicated positive causality with MGMs, while 22 metabolites displayed a remarkable negative causality. In particular, plasma levels of Glycerol 3-phosphate (G3P) (OR=4.76, 95% CI=1.02-22.12, P=0.047) and Valine (OR=0.025, 95% CI=0.0020-0.42, P=0.010) were found to exhibit the optimal efficacy. Multiple sensitivity analyses confirm the robustness of the results. The study found no evidence of a reverse causality between MGMs and the plasma levels of Glycerol 3-phosphate (G3P) and Valine. Conclusion: This study identified 36 metabolites associated with the incidence of MGMs, among which Glycerol 3-phosphate (G3P) and Valine are the most notable findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.